Image

Preventing Maternal Mood, Anxiety, and Trauma Symptoms After Cesarean Delivery

Preventing Maternal Mood, Anxiety, and Trauma Symptoms After Cesarean Delivery

Recruiting
Female
Phase N/A

Powered by AI

Overview

Perinatal mental health disorders are the most prevalent perinatal comorbidity and are associated with the primary cause of maternal mortality in the United States (US) - suicide. Diagnosis of a high-risk pregnancy and cesarean delivery (CD) are both associated with increased risk for perinatal mood, anxiety, and trauma symptoms (PMATS). There is a deficit in resources and access to mental health treatment for pregnant patients, with some treatments being cost-prohibitive and requiring multiple sessions. Additionally, current approaches to addressing PMATS are reactive rather than preventive. There is evidence in the non-obstetric population that single-session cognitive behavioral therapy interventions targeting anxiety sensitivity (fear of fear) can prevent the development of anxiety and trauma symptoms when individuals are exposed to trauma. The investigators developed a low-cost, 1-hour, single-session prevention intervention that included psychoeducation about anxiety sensitivity, coupled with a brief exposure to the operating room environment and CD procedures. To revise the implementation plan and intervention (CARE: Communication, Agency, Readiness, Empowerment for cesarean delivery [CD]) for use in large L&D units with a broader population of patients, a fully powered multisite randomized control trial (RCT) is needed. Before initiating such a trial, work needs to be done to modify the intervention and implementation through a process of iterative refinement to enhance the acceptability, appropriateness, and feasibility of implementation in L&D units across the country, as well as its efficacy at engaging with the target mechanism (anxiety sensitivity). Using a logic model to guide the iterative refinement process through fast feedback loops and an atmosphere of co-creation, study investigators will gather critical input from stakeholders (individuals with lived experiences, community partners, front-line clinicians, and hospital staff) via 12 workgroups, 12 user-testing design sessions, and repeated engagement with a steering council. Following this refinement process, a treatment development pilot RCT at a large L&D unit will assess the efficacy of CARE for CD by probing engagement with the target mechanism, as well as assess the feasibility of implementation. Finally, the updated logic model and pilot trial results will inform the development of a protocol for a multisite RCT through engagement with expert consultants in a community engagement studio and further feedback from the steering council.

Description

Postpartum mental health disorders disproportionately occur among the 1 million patients with cesarean deliveries (CD) in the United States (US) each year, with 1 in 3 reporting elevated symptoms of postpartum mood, anxiety, and trauma symptoms (PMATS). Brief, single-session interventions that target anxiety sensitivity (AS) through psychoeducation + exposure have been shown to prevent the development of anxiety and trauma symptoms in non-perinatal populations. Thus, a single session AS-targeted intervention involving psychoeducation about AS + in-vivo exposure to the operating room (OR) and CD procedures may be an effective intervention to prevent the development of PMATS. The primary objective of this proposal is to refine and pilot a 1-hour, single-session brief exposure intervention in the OR (CARE) to reduce AS and thus prevent the development of PMATS among a population of patients with high-risk pregnancies and anticipated CD.

The investigators initially developed CARE for implementation in a maternal-fetal care unit at a children's hospital that has 12 beds, an average daily census of 6 patients, and 130 CDs/year. In this unit, the investigators conducted a pilot RCT study of CARE among a population of pregnant patients at very high risk for PMATS (those with anomalous fetuses). Those who received CARE reported 42% less preoperative anxiety and 40% less postpartum anxiety symptoms at 6-8 weeks following delivery, and significantly less opioid use at postoperative days 2-4 than those who received care as usual. While these results demonstrate the promise of the intervention, its scalability to large L&D units and a broader population of patients is not established, and a fully powered, multisite randomized controlled trial (m-RCT) is needed. Before the m-RCT, the intervention must be refined to improve its acceptability, appropriateness, and feasibility for implementation in broader contexts with the desired impact on the target mechanism and outcomes. The proposed project engages in Stage 1A/B activities across three phases. Phase 1 involves a process of iterative refinement using key stakeholder workgroups, user-testing design, and repeated engagement with a steering council (SC) in fast feedback loops to facilitate information flow and foster co-creation. Phase 2 involves the design and implementation of a treatment development trial with an emphasis on feasibility, fidelity, and safety, as well as probing efficacy of engagement with the hypothesized mechanism of CARE (AS) at a single large L&D unit with 50 beds, an average daily census of 34 patients, and 1,000 CDs/year. Phase 3 will involve one additional cycle of rapid iterative refinement to prepare for a future m-RCT with L&D units across the US. Identified future m-RCT site-based investigators and associated administrators will participate in a community engagement studio to refine/co-create a finalized implementation protocol for the m-RCT to take to the SC for final approval.

Specific Aim 1: To enhance the efficacy, responsiveness to diverse populations, scalability, and sustainability of CARE for implementation in large L&D units by engaging in an iterative refinement process guided by an Implementation Research Logic Model (IRLM) framework,12 which allows the team to rapidly iterate based on feedback in Plan-Do-Check-Act cycles using 12 workgroups, 12 user-testing design sessions, and repeated engagement with a SC comprised of stakeholders from across the country (clinicians/hospital staff and those with lived experiences/community partners).

Hypothesis 1: Some barriers and determinants must be addressed to refine CARE and its implementation so that it is acceptable and engages the target mechanism in a diverse population of patients and may be incorporated into workflows on L&D units.

Specific Aim 2: To probe the efficacy of CARE at reducing AS and preventing PMATS using a treatment development trial with high-risk antepartum patients anticipating CD by comparing outcomes among participants randomized to CARE (N=40), Interaction Control (N=20), or Care as Usual Control (N=20) and to establish feasibility, safety, and acceptability of CARE implementation.

Hypothesis 2a: In comparison to patients who receive either control condition, those who receive CARE will have decreased AS before CD.

Hypothesis 2b: Decreased AS before CD will be associated with fewer symptoms of PMATS at 12 weeks postpartum.

Hypothesis 2c: CARE will be administered with high fidelity, yield minimal safety events, and have high acceptability.

Impact Statement: This study is a critical step in preventing PMATS which are among the leading causes of maternal mortality in the US. This study will be the first in a long line of research broadening to additional risk groups, perinatal care settings, and intervention modalities (e.g., virtual reality, nurse- or peer-facilitated).

Eligibility

Inclusion Criteria:

  • Pregnant Patients at 22-37 weeks gestation
  • Single or multiple gestation
  • Nulliparous or multiparous (with prior vaginal or cesarean delivery)
  • Antepartum admission for at least 3 days
  • High-risk pregnancy due to maternal/fetal comorbidities
  • Anticipated cesarean delivery at the University of Colorado

Exclusion Criteria:

  • Lack of capacity to consent
  • Medical factors prohibiting participation in the intervention as determined by the inpatient obstetric medical team.
  • Anticipated cesarean within 7 days of enrollment

Study details
    Anxiety in Pregnancy
    Mood Disorder Due to Specified Medical Condition

NCT06949813

University of Colorado, Denver

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.